Splenic Marginal Zone Lymphoma
New splenic marginal zone lymphoma research, summarized each month in plain language.
2026 so far: So far in 2026 (January 2026 to July 2026), confirming the diagnosis (often with tissue) repeatedly changed how SMZL was labeled, while case reports described rituximab-based responses and rare complications around rituximab-based care. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Rituximab outcomes and risks. Single-patient reports described both improvement and safety concerns.
- Rare complications. Some reports focused on uncommon symptoms and the supportive care they required.
- Who needs treatment. Cohort and registry studies added signals about risk and follow-up needs.
- Getting the diagnosis right. Reports showed that imaging and symptoms alone often could not sort out the cause.
- Biology risk groups. Exploratory studies proposed measurable subgroups linked to outcome signals.
New
July 2026
- Slow disease course. Most early marginal zone-type B-cell findings stayed stable for years.
- Treatment risk factors. More bone marrow involvement and higher LDH were tied to later treatment.
- Unusual bleeding disorder. One report linked acquired hemophilia A with SMZL around diagnosis.
- Hepatitis B reactivation. One report described hepatitis B returning during rituximab-based treatment.
June 2026
- Blood smear changes. More nucleus changes matched more complex chromosome changes.
- Similar lymphoma types. Added testing sometimes changed the diagnosis to a related lymphoma.
- Rituximab case reports. Two case reports improved after rituximab-based treatment.
May 2026
- Two biology groups. One study found two SMZL groups with different outcomes.
- Research-only marker. This DNA methylation grouping is not a routine clinical test.
April 2026
- How often diagnosed. One hospital review found SMZL in 3.4% of lymphoma cases.
- Symptom care evidence. This month added no new evidence on symptom care.
- Treatment evidence. This month included no SMZL treatment-focused studies.
February 2026
- Spleen rupture. SMZL may first be found after a sudden spleen rupture.
- Warm autoimmune anemia. Severe immune red-cell breakdown may be the first sign.
- Abdominal fluid testing. Abdominal fluid tests may miss lymphoma even when present.
- R-CVP remission. One reported patient had complete remission after R-CVP.
January 2026
- Spleen tissue testing. Spleen tissue helped separate SMZL from faster-growing lymphoma.
- Chylous ascites. Rituximab plus a BTK inhibitor cleared chylous ascites in one case.
- Separate origins. Genetic findings suggested SMZL and DLBCL may start separately.
Get the monthly update by email
Subscribe here to receive an email when a new monthly splenic marginal zone lymphoma update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).